GEOVAX LABS INC (GOVX)
US3736786068 - Common Stock
Overall GOVX gets a fundamental rating of 2 out of 10. We evaluated GOVX against 561 industry peers in the Biotechnology industry. While GOVX seems to be doing ok healthwise, there are quite some concerns on its profitability. GOVX does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
GOVX had negative earnings in the past year.
In the past year GOVX has reported a negative cash flow from operations.
In the past 5 years GOVX always reported negative net income.
GOVX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
With a Return On Assets value of -218.88%, GOVX is not doing good in the industry: 91.35% of the companies in the same industry are doing better.
GOVX has a Return On Equity of -286.01%. This is in the lower half of the industry: GOVX underperforms 73.69% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -218.88% | ||
| ROE | -286.01% | ||
| ROIC | N/A |
ROA(3y)-160.62%
ROA(5y)-203.16%
ROE(3y)-309.67%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for GOVX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
GOVX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, GOVX has more shares outstanding
GOVX has more shares outstanding than it did 5 years ago.
There is no outstanding debt for GOVX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
Based on the Altman-Z score of -15.63, we must say that GOVX is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -15.63, GOVX is not doing good in the industry: 83.96% of the companies in the same industry are doing better.
GOVX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -15.63 |
ROIC/WACCN/A
WACC10.63%
2.3 Liquidity
A Current Ratio of 4.17 indicates that GOVX has no problem at all paying its short term obligations.
With a Current ratio value of 4.17, GOVX perfoms like the industry average, outperforming 47.57% of the companies in the same industry.
GOVX has a Quick Ratio of 4.17. This indicates that GOVX is financially healthy and has no problem in meeting its short term obligations.
GOVX has a Quick ratio (4.17) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.17 | ||
| Quick Ratio | 4.17 |
3. Growth
3.1 Past
The earnings per share for GOVX have decreased strongly by -42.10% in the last year.
The Revenue for GOVX has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)-42.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%81.04%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
GOVX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.03% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y78.27%
EPS Next 2Y39.52%
EPS Next 3Y25.03%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
GOVX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year GOVX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
GOVX's earnings are expected to grow with 25.03% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.52%
EPS Next 3Y25.03%
5. Dividend
5.1 Amount
GOVX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
GEOVAX LABS INC
NASDAQ:GOVX (1/6/2025, 5:03:54 PM)
After market: 2.65 +0.05 (+1.92%)2.6
-0.04 (-1.52%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners10.19%
Inst Owner Change0%
Ins Owners0.81%
Ins Owner Change0.58%
Market Cap24.54M
Analysts81.82
Price Target14.89 (472.69%)
Short Float %5.44%
Short Ratio0.27
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)40.82%
Min EPS beat(2)39.62%
Max EPS beat(2)42.02%
EPS beat(4)3
Avg EPS beat(4)-60.53%
Min EPS beat(4)-380.19%
Max EPS beat(4)56.45%
EPS beat(8)5
Avg EPS beat(8)-34.24%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.82%
PT rev (3m)-65.24%
EPS NQ rev (1m)0%
EPS NQ rev (3m)61.06%
EPS NY rev (1m)-6.67%
EPS NY rev (3m)25.05%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)3.21%
Revenue NY rev (3m)177.47%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 7.94 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 2.89 | ||
| P/tB | 2.89 | ||
| EV/EBITDA | N/A |
EPS(TTM)-18.97
EYN/A
EPS(NY)-1.28
Fwd EYN/A
FCF(TTM)-2.89
FCFYN/A
OCF(TTM)-2.88
OCFYN/A
SpS0.33
BVpS0.9
TBVpS0.9
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -218.88% | ||
| ROE | -286.01% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-160.62%
ROA(5y)-203.16%
ROE(3y)-309.67%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.28
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 41.33% | ||
| Cap/Sales | 1.28% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.17 | ||
| Quick Ratio | 4.17 | ||
| Altman-Z | -15.63 |
F-Score4
WACC10.63%
ROIC/WACCN/A
Cap/Depr(3y)142.83%
Cap/Depr(5y)262.98%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-42.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%81.04%
EPS Next Y78.27%
EPS Next 2Y39.52%
EPS Next 3Y25.03%
EPS Next 5YN/A
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-0.23%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-89053.1%
EBIT Next 3Y-897.7%
EBIT Next 5YN/A
FCF growth 1Y-45.02%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-45.85%
OCF growth 3YN/A
OCF growth 5YN/A